Patent FR-2893630-A1 (FR)
Title: Treating cells genetically/epigenetically to treat diseases, involves contacting nucleus of to-be-treated cell with genetic reprogramming medium having natural cytoplasm of genetic reprogramming cell, to modify biological age
Inventor: ZACOUTO FRED
IPC: C12N5/075
Filed: 2005-11-21
Abstract: Genetic and epigenetic treatment process for to-be-treated cells, involves supplying at least one to-be-treated cell, supplying a genetic reprogramming medium (GRM) comprising at least natural cytoplasm of at least one genetic reprogramming cell (GRC) and/or synthetic cytoplasm, and bringing at least portion of at least one nucleus of one or more to-be-treated cell into contact with the GRM to modify the biological age and/or to repair the one or more to-be-treated cell. Genetic and epigenetic treatment process for to-be-treated cells, involves supply of at least one to-be-treated cell, supplying a genetic reprogramming medium (GRM) comprising at least natural cytoplasm of at least one genetic reprogramming cell (GRC) and/or synthetic cytoplasm, and bringing at least portion of at least one nucleus of at least one to-be-treated cell into contact with the GRM to modify the biological age and/or to repair the to-be-treated cell. Process for genetic and epigenetic treatment, involves use of at least one genetic reprogramming cell and at least one differentiated cell for fabrication of at least one regenerated differentiated cell capable of being reimplanted to treat various pathologies, diseases and/or tissue insufficiencies, involves supplying at least one GRC formed of an oocyte or an embryonic cell, supplying at least one differentiated cell, preferably completely removing the nucleus from the GRC, removing and transferring the nucleus of a differentiated cell into the GRC, extracting the nucleus of the differentiated cell transferred into the GRC, before the end of its first mitosis, and introducing the nucleus of the extracted differentiated cell into a differentiated cell, preferably from which its nucleus has been removed and preferably autologous, so as to form a regenerated differentiated cell, multiplying the regenerated differentiated cell. Independent claims are included for: (1) cancer treatment process, involves removal of at least one hematopoietic cell at the bone marrow or its periphery, supplying GRM, putting at least a portion of a nucleus of removed hematopoietic cell into contact with the GRM, separating at least portion of a nucleus of a removed hematopoietic cell from the GRM, introducing at least the portion of a nucleus of a hematopoietic cell thus separated in an hematopoietic receiving cell, preferably from which its nucleus has been removed, preferably autologous, to rejuvenate the hematopoietic receiving cell, multiplying the rejuvenated receiving cell in vitro, and reinjecting the rejuvenated cells to combat cancer; (2) system (S1) for genetic and epigenetic treatment process for to-be-treated cells, comprising at least one to-be-treated cell, GRM, and unit for bringing at least a portion of at least one nucleus of to-be-treated cell into contact with the GRM, to modify the biological age and/or repair the to-be-treated cell; and (3) system (S2) for genetic regeneration of differentiated cells, comprising at least one differentiated cell, unit for cell reprogramming, comprising at least one GRC formed of an oocytes or an embryonic cell, unit for removing the nucleus of at least one GRC, preferably completely, unit for removing and transferring the nucleus of a differentiated cell into a corresponding GRC, unit for extracting the transferred nucleus of the differentiated cell from the GRC, before the end of its first mitosis, and unit for introducing the nucleus of the extracted differentiated cell into a differentiated receiving cell, preferably from which its nucleus has been removed and preferably autologous, the receiving cell then being a regenerated cell capable of multiplying, the resulting tissue being designed to be positioned within a to be-regenerated tissue. ACTIVITY : Cytostatic; Antiulcer; Antiarthritic; Osteopathic; Hepatotropic; Cardiant. No biological data given. MECHANISM OF ACTION : Cell therapy.